BR112018015826A2 - anticorpos monoclonais específicos egfl6 e métodos de seu uso - Google Patents
anticorpos monoclonais específicos egfl6 e métodos de seu usoInfo
- Publication number
- BR112018015826A2 BR112018015826A2 BR112018015826A BR112018015826A BR112018015826A2 BR 112018015826 A2 BR112018015826 A2 BR 112018015826A2 BR 112018015826 A BR112018015826 A BR 112018015826A BR 112018015826 A BR112018015826 A BR 112018015826A BR 112018015826 A2 BR112018015826 A2 BR 112018015826A2
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibodies
- egfl6
- methods
- specific monoclonal
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
são fornecidos anticorpos monoclonais anti-egfl6 isolados ou recombinantes. em alguns casos, os anticorpos das modalidades podem ser usados para a detecção, o diagnóstico e/ou o tratamento terapêutico de doenças humanas, tais como câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291987P | 2016-02-05 | 2016-02-05 | |
PCT/US2017/016659 WO2017136807A1 (en) | 2016-02-05 | 2017-02-06 | Egfl6 specific monoclonal antibodies and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018015826A2 true BR112018015826A2 (pt) | 2019-01-02 |
Family
ID=59501106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018015826A BR112018015826A2 (pt) | 2016-02-05 | 2017-02-06 | anticorpos monoclonais específicos egfl6 e métodos de seu uso |
Country Status (12)
Country | Link |
---|---|
US (2) | US10875912B2 (pt) |
EP (1) | EP3411070A4 (pt) |
JP (3) | JP2019512210A (pt) |
KR (1) | KR20180105704A (pt) |
CN (2) | CN113912717B (pt) |
AU (1) | AU2017214685B2 (pt) |
BR (1) | BR112018015826A2 (pt) |
CA (1) | CA3012696A1 (pt) |
MX (1) | MX2018009499A (pt) |
SG (1) | SG11201806622PA (pt) |
WO (1) | WO2017136807A1 (pt) |
ZA (1) | ZA201805051B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180105704A (ko) * | 2016-02-05 | 2018-09-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Egfl6 특이적 단일클론 항체들 및 이의 사용 방법 |
CN111787946B (zh) * | 2017-10-01 | 2023-08-15 | 台北医学大学 | 抗-类egf结构域多重6(egfl6)抗体及其于癌症诊断及治疗中的应用 |
EP3902830A1 (en) * | 2018-12-30 | 2021-11-03 | F. Hoffmann-La Roche AG | Anti-rabbit cd19 antibodies and methods of use |
CN110951733A (zh) * | 2019-11-27 | 2020-04-03 | 山西医科大学 | 一种靶向抑制食管癌EGFL6基因表达的siRNA及构建的表达载体和应用 |
CN116381251A (zh) * | 2023-03-13 | 2023-07-04 | 广州鹏翔生物技术有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2174957T5 (es) * | 1994-07-29 | 2006-12-16 | Innogenetics N.V. | Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico. |
US20030036508A1 (en) * | 1997-11-22 | 2003-02-20 | John Ford | EGF motif protein, EGFL6 materials and methods |
EP1356045A2 (en) * | 2000-10-13 | 2003-10-29 | Nuvelo, Inc. | Egf motif protein, egfl6 materials and methods |
EP2471936A3 (en) * | 2005-11-24 | 2013-04-24 | The Research Foundation for Microbial Diseases of Osaka University | Recombinant polyvalent vaccine |
AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
DK2307454T3 (en) * | 2008-06-25 | 2017-04-24 | Esbatech Alcon Biomed Res Unit | Stable and soluble antibodies that inhibit VEGF |
US8501197B2 (en) * | 2010-04-30 | 2013-08-06 | The Research Foundation for The State of New York | Compositions and methods for stimulating immune response against Moraxella catarrhalis |
AU2012310328A1 (en) * | 2011-09-23 | 2014-04-10 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Anti-Tumor Necrosis Factor-alpha agents and uses thereof |
US9850300B2 (en) * | 2013-03-15 | 2017-12-26 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting cancer cell growth and/or proliferation |
AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
KR20180105704A (ko) * | 2016-02-05 | 2018-09-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Egfl6 특이적 단일클론 항체들 및 이의 사용 방법 |
-
2017
- 2017-02-06 KR KR1020187024950A patent/KR20180105704A/ko unknown
- 2017-02-06 EP EP17748334.4A patent/EP3411070A4/en active Pending
- 2017-02-06 SG SG11201806622PA patent/SG11201806622PA/en unknown
- 2017-02-06 AU AU2017214685A patent/AU2017214685B2/en active Active
- 2017-02-06 BR BR112018015826A patent/BR112018015826A2/pt unknown
- 2017-02-06 MX MX2018009499A patent/MX2018009499A/es unknown
- 2017-02-06 CN CN202110985801.8A patent/CN113912717B/zh active Active
- 2017-02-06 JP JP2018540833A patent/JP2019512210A/ja active Pending
- 2017-02-06 US US16/075,711 patent/US10875912B2/en active Active
- 2017-02-06 WO PCT/US2017/016659 patent/WO2017136807A1/en active Application Filing
- 2017-02-06 CN CN201780015519.9A patent/CN109562163B/zh active Active
- 2017-02-06 CA CA3012696A patent/CA3012696A1/en active Pending
-
2018
- 2018-07-26 ZA ZA2018/05051A patent/ZA201805051B/en unknown
-
2020
- 2020-11-12 US US17/096,280 patent/US20210130450A1/en active Pending
-
2021
- 2021-08-30 JP JP2021139610A patent/JP7358426B2/ja active Active
-
2023
- 2023-06-29 JP JP2023106822A patent/JP2023130411A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109562163A (zh) | 2019-04-02 |
MX2018009499A (es) | 2019-05-06 |
CN113912717B (zh) | 2024-05-03 |
KR20180105704A (ko) | 2018-09-28 |
EP3411070A4 (en) | 2019-11-27 |
SG11201806622PA (en) | 2018-09-27 |
US20190031751A1 (en) | 2019-01-31 |
CA3012696A1 (en) | 2017-08-10 |
WO2017136807A1 (en) | 2017-08-10 |
JP2023130411A (ja) | 2023-09-20 |
RU2018131611A3 (pt) | 2020-05-19 |
US20210130450A1 (en) | 2021-05-06 |
US10875912B2 (en) | 2020-12-29 |
ZA201805051B (en) | 2023-05-31 |
CN109562163B (zh) | 2022-04-08 |
AU2017214685A1 (en) | 2018-08-09 |
CN113912717A (zh) | 2022-01-11 |
EP3411070A1 (en) | 2018-12-12 |
RU2018131611A (ru) | 2020-03-05 |
AU2017214685B2 (en) | 2024-03-07 |
JP7358426B2 (ja) | 2023-10-10 |
JP2022008309A (ja) | 2022-01-13 |
JP2019512210A (ja) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018015826A2 (pt) | anticorpos monoclonais específicos egfl6 e métodos de seu uso | |
GEP20237528B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
MX2023000781A (es) | Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos. | |
BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
EP3707272A4 (en) | EXTRACELLULAR VESICLE PROTEINS AND THEIR USE IN CANCER DIAGNOSIS, PROGNOSIS OF RESPONSE TO THERAPY AND TREATMENT | |
BR112017025529A2 (pt) | agentes de ligação ao tigit e usos destes | |
BR112018005322A2 (pt) | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos | |
BR112016025437A2 (pt) | combinação de lenalidomida e construto de polipeptídeo, e usos destes | |
EA202190903A2 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
EA201792441A2 (ru) | Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
BR112015013127A2 (pt) | imunoterapia com agentes de ligação | |
BR112016017986A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo | |
EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
BR112018000653A2 (pt) | anticorpo anti-cd154 tendo características melhoradas de ligação, funcionais e de segurança e uso na imunoterapia humana | |
BR112019005944A2 (pt) | anticorpos que se ligam à interleucina 2 e usos dos mesmos | |
CL2019000846A1 (es) | Proteína terapéutica. | |
EA201591796A1 (ru) | Антитела к cd52 | |
BR112017003487A2 (pt) | ?anticorpo totalmente humano, fragmento de fab de anticorpo totalmente humano, anticorpo humano de fita simples, anticorpo de fita simples totalmente humano, método de tratamento de amplo espectro de cânceres e método de tratamento de distúrbios inflamatórios? | |
BR112019020386A2 (pt) | vacinas de peptídeos de pd-1 humana e usos das mesmas | |
EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |